GBH Insights’ Daniel Ives sizes up impressive standing for Amazon to gain further sporting rights following its newest “‘game-changing’ move.”
Mizuho’s Difei Yang offers a bullish take on NKTR stock in a week that saw Wall Street running for the hills on the drug maker.
Oppenheimer’s Jay Olson finds it encouraging to see AXON evolving its pipeline to gene therapy.
Seeking Alpha’s Ben Rabizadeh has sold off all his remaining HMNY shares on his once “big speculative play.”
Needham’s Rajvindra Gill believes that once Tesla’s Model 3 achieves its targets, the leverage at play is meaningful.
Roth Capital’s Sujeeva De Silva now calls for just 4% in return potential for AMBA shares following an underwhelming FQ2:19 guide.
GBH Insights’ Daniel Ives sees negativity that could hit at FB amid the China news, but recognizes a knack for “snap back recovery.”
Rosenblatt’s Hans Mosesmann sheds bullish light on AMD following Monday’s Computex conference in Taiwan.
Here’s a glimpse into how one of Wall Street’s most successful hedge fund gurus chose to bet on Micron and Tesla in Q1.